期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
IL-33、TIMP-1、MMP-2联合乙肝五项指标诊断慢性HBV肝纤维化的应用价值 被引量:8
1
作者 张意钗 罗胜强 岑美婷 《临床和实验医学杂志》 2022年第13期1387-1390,共4页
目的研究白细胞介素-33(IL-33)、金属蛋白酶组织抑制因子1(TIMP-1)及基质金属蛋白酶-2(MMP-2)联合乙肝五项指标诊断慢性HBV肝纤维化的应用价值。方法回顾性选取2020年1月至2021年12月于广州市第一人民医院南沙医院接受诊断的慢性HBV肝... 目的研究白细胞介素-33(IL-33)、金属蛋白酶组织抑制因子1(TIMP-1)及基质金属蛋白酶-2(MMP-2)联合乙肝五项指标诊断慢性HBV肝纤维化的应用价值。方法回顾性选取2020年1月至2021年12月于广州市第一人民医院南沙医院接受诊断的慢性HBV肝纤维化患者116例纳入研究组,肝纤维化分期:S1期16例,S2期39例,S3期47例,S4期14例。另同期体检健康志愿者116名纳入对照组。比较两组、研究组不同肝纤维化分期患者血清IL-33、TIMP-1、MMP-2水平。分析研究组乙肝五项患者在不同肝纤维化分期中的分布。分析乙肝五项、IL-33、TIMP-1、MMP-2与肝纤维化分期的相关性。结果研究组血清IL-33、TIMP-1、MMP-2水平为(562.86±59.30)pg/mL、(185.16±21.03)μg/L、(443.87±47.06)μg/L,均分别高于对照组[(142.96±17.35)pg/mL、(127.53±14.86)μg/L、(249.86±27.76)μg/L],差异均有统计学意义(P<0.05)。研究组不同肝纤维化分期血清IL-33、TIMP-1、MMP-2水平差异均有统计学意义(P<0.05)。研究组乙肝五项患者在不同肝纤维化分期患者中的分布差异均有统计学意义(P<0.05)。大三阳、小三阳及IL-33、TIMP-1、MMP-2与肝纤维化分期均呈正相关(r=0.430、0.368、0.462、0.538、0.528,P<0.05)。HBsAg阴性、1.4阳性、1.5阳性与肝纤维化分期均无相关性(P>0.05)。结论慢性HBV肝纤维化患者大三阳、小三阳及IL-33、TIMP-1、MMP-2与肝纤维化分期呈正相关,IL-33、TIMP-1、MMP-2联合乙肝五项指标对慢性HBV肝纤维化具有较高的诊断价值。 展开更多
关键词 慢性HBV 肝纤维化 白细胞介素-33 金属蛋白酶组织抑制因子1 基质金属蛋白酶-2 乙肝五项指标
下载PDF
San-Cao Granule (三草颗粒) Ameliorates Hepatic Fibrosis through High Mobility Group Box-1 Protein/Smad Signaling Pathway 被引量:2
2
作者 WEI Shi-zhang luo sheng-qiang +15 位作者 WANG Jian WANG Jia-bo LI Rui-sheng ZHANG Xiao-mei GUO Yan-lei CHEN Chang MA Xiao CHEN Zhe LIU Hong-hong YANG Zhi-rui LI Jian-yu WANG Rui-lin ZHANG Ya-ming YANG Hui-yin XIAO Xiao-he ZHAO Yan-ling 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2018年第7期502-511,共10页
Objective: To investigate the possible mechanism of San-Cao Granule(SCG, 三草颗粒) mediating antiliver fibrosis. Methods: A total of 60 male Sprague-Dawley rats were randomly divided into the normal control group,... Objective: To investigate the possible mechanism of San-Cao Granule(SCG, 三草颗粒) mediating antiliver fibrosis. Methods: A total of 60 male Sprague-Dawley rats were randomly divided into the normal control group, porcine serum-treated group, ursodesoxycholic acid(UDCA, 60 mg/kg), SCG(3.6 g/kg) group, SCG(1.8 g/kg) group and SCG(0.9 g/kg) group, with 10 rats in each group. Liver fibrosis was induced with porcine serum by intraperitoneal injection for 8 weeks, except for the normal control group. Then, the rats in the three SCG-treated groups and UDCA group were administered SCG and UDCA respectively for 4 weeks. The serum levels of alanine transaminase(ALT), aspartate transaminase(AST), albumin(ALB), total bilirubin(TBIL), hyaluronic acid(HA), laminin(LN), and type Ⅳcollagen(ⅣC) were examined using commercial kits and hepatic histopathology was examined with hematoxylin and eosin and Masson staining. Moreover, the protein expression levels of high mobility group box-1 protein(HMGB1), transforming growth factor β1(TGF-β1), phosphorylated mothers against decapentaplegic homolog 3(p-Smad3), Smad7, toll-like receptor 4(TLR4), myeloid differentiation factor 88(My D88), nuclear factor-kappa B(NF-κB) and α-smooth muscle actin(α-SMA) were determined by western blot, immunohistochemistry and real time quantitativereverse transcription polymerase. Results: Both SCG(3.6 and 1.8 g/kg) and UDCA significantly ameliorated the liver fibrosis induced by porcine serum as indicated by retarding the serum levels increasing of ALT, AST, TBIL, HA, LN and ⅣC and preventing the serum level reducing of ALB compared with the model group(all P〈0.01). Meanwhile, the collagen deposition was attenuated by SCG and UDCA treatment. Furthermore, SCG markedly reduced the expressions of HMGB1, TGF-β1, p-Smad3, TLR4, My D88, NF-κB and α-SMA, and enhanced the expression of the Smad7 compared with the model group(all P〈0.01). Conclusion: SCG ameliorates hepatic fibrosis possibly through inhibiting HMGB1, TLR4/NF-κB and TGF-β1/Smad signaling pathway. 展开更多
关键词 San-Cao Granule liver fibrosis high mobility group box-1 protein toll-like receptor 4/nuclear factor-kappa B transforming growth factor β1/mothers against decapentaplegic homolog
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部